Structure Therapeutics (GPCR) director Waldstreicher received 51,804 Share Option (right to buy)
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
Joanne Waldstreicher (director at Structure Therapeutics Inc., GPCR) reported that they received 51,804 Share Option (right to buy) on Jun 23, 2025.
- Reporting person
- Waldstreicher Joanne
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jun 23, 2025 | Grant or award (A) | Share Option (right to buy)On 51,804 Ordinary Shares1, 2, 3 | +51,804 | - | - | 51,804 direct |
Holdings before and after
- Share Option (right to buy): 0 to 51,804 direct
Footnotes from the filing
- 1. The option exercise price per share is equal to the fair market value per Ordinary Share on the grant date based on the trading price of the Issuer's American Depositary Shares ( ADSs ).
- 2. The shares vest in equal monthly installments over the 12 months following June 23, 2025, provided that the grant will in any case be fully vested on the date immediately prior to the date of the Issuer's 2026 annual shareholder meeting,
- 3. The Ordinary Shares of the Issuer may be represented by ADSs. Each ADS represents three Ordinary Shares of the Issuer.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Waldstreicher report in this GPCR Form 4?
Joanne Waldstreicher (director at Structure Therapeutics Inc., GPCR) reported that they received 51,804 Share Option (right to buy) on Jun 23, 2025.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for GPCR
Earlier insider filings at GPCR
- Jun 25, 2025SEC Form 4 filed by Director Tetlow Sharon
- Jun 25, 2025SEC Form 4 filed by Director Dobmeier Eric
- Jun 25, 2025SEC Form 4 filed by Director Welch Daniel G
- Mar 19, 2025Chief Development Officer Hall Ashley was granted 51,048 units of Ordinary Shares, increasing direct ownership by 76% to 118,338 units (SEC Form 4)
- Mar 19, 2025CHIEF TECHNOLOGY OFFICER Ma Yingli was granted 63,810 units of Ordinary Shares, increasing direct ownership by 174% to 100,539 units (SEC Form 4)
Keep researching GPCR
- GPCR insider tradesEvery buy and sale reported by Structure Therapeutics Inc. officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- GPCR earnings historyPast Structure Therapeutics Inc. earnings releases, newest first.
- GPCR financial statementsRevenue, profit, cash flow and balance sheet from Structure Therapeutics Inc.'s SEC filings.
Quantisnow market dataNASDAQ
GPCR
Structure Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2023
Get push alerts for GPCR
Full GPCR profile on Quantisnow Follow GPCR and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time